Chugai Pharmaceutical Co., Ltd. CHGCF
OTC PK
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -0.99% | 13.20% | -3.34% | 23.72% | |
| Total Other Revenue | 57.87% | 14.55% | 18.53% | -13.79% | |
| Total Revenue | 6.78% | 13.44% | -0.93% | 18.58% | |
| Cost of Revenue | 7.28% | -8.12% | 8.08% | 17.26% | |
| Gross Profit | 6.56% | 23.23% | -4.41% | 19.17% | |
| SG&A Expenses | -7.33% | 12.71% | 12.25% | 0.21% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | 97.01% | 245.74% | -1,480.33% | -193.72% | |
| Total Operating Expenses | 6.86% | -1.81% | 4.99% | 7.87% | |
| Operating Income | 6.68% | 35.53% | -6.82% | 33.27% | |
| Income Before Tax | 12.67% | 33.96% | -7.58% | 32.45% | |
| Income Tax Expenses | 22.97% | 20.95% | -10.69% | 47.49% | |
| Earnings from Continuing Operations | 8.55% | 38.78% | -6.27% | 27.30% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 8.55% | 38.78% | -6.27% | 27.30% | |
| EBIT | 6.68% | 35.53% | -6.82% | 33.27% | |
| EBITDA | 6.83% | 28.91% | -6.79% | 33.13% | |
| EPS Basic | 8.54% | 38.85% | -6.26% | 27.28% | |
| Normalized Basic EPS | 12.67% | 34.03% | -7.60% | -- | |
| EPS Diluted | 8.54% | 38.83% | -6.26% | 27.28% | |
| Normalized Diluted EPS | 12.67% | 34.03% | -7.57% | -- | |
| Average Basic Shares Outstanding | 0.00% | -0.05% | 0.01% | 0.01% | |
| Average Diluted Shares Outstanding | 0.00% | -0.03% | 0.00% | 0.01% | |
| Dividend Per Share | 19.67% | 24.99% | 31.63% | -- | |
| Payout Ratio | -- | -- | -0.07% | -- | |